Clinical Context
A typical patient is an adult with relapsing-remitting multiple sclerosis (RRMS) receiving maintenance infusion therapy with natalizumab biosimilar Q5134 (natalizumab-sztn, Tyruko) dosed per manufacturer guidance. The clinical workflow begins with outpatient neurology infusion center scheduling for an infusion appointment. Pre-visit steps include verification of diagnosis, review of prior infusion tolerance, screening for progressive multifocal leukoencephalopathy (PML) risk (including John Cunningham virus serology and prior immunosuppressant history), baseline vital signs, and review of pregnancy status for women of childbearing potential.
On the day of service the patient arrives to an infusion suite or hospital outpatient infusion center. A registered nurse performs an intake assessment, documents allergies, obtains baseline vitals, and establishes intravenous access if required (depending on product formulation and institutional protocol). The pharmacy verifies medication preparation and label, including dose calculated from the medication order and expiry. The provider documents informed consent for off-label or biosimilar substitution if required by facility policy. The infusion is administered under nursing supervision with monitoring for infusion-related reactions; medications for acute hypersensitivity are available. Post-infusion observation is typically 30–60 minutes depending on prior tolerance. Billing uses HCPCS Level II code Q5134 for the drug product (per mg unit), with appropriate modifiers appended when clinically relevant and with an infusion administration CPT code billed by the facility or clinician as applicable.